Back to search results

A Phase I/Ib, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BDTX-1535, an Inhibitor of Allosteric EGFR Mutations, as Monotherapy or Combination Therapy for Patients with Advanced Glioblastoma or Non-small Cell Lung Cancer

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
I

ClinicalTrials.gov Identifier:
NCT05256290

Study #:
STUDY00150735

Start Date:
Jan 29, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05256290

View Complete Trial Details & Eligibility at ClinicalTrials.gov